Compounds and methods for treating oxalate-related diseases
AssigneeOxaluRx, Inc.
InventorsBradley T. KELLER, John J. TALLEY
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.
Claims44
A pharmaceutical composition comprising a compound of structural Formula Ia
- or a salt or prodrug thereof, wherein:
- W is N or NH;
- Y is N if W is NH;
- Y is NH if W is N;
- R1 is chosen from hydrogen and C1-C6 alkyl;
- L is O;
- R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
- A is chosen from monocyclic or bicyclic aryl, monocyclic or bicyclic heteroaryl, biaryl, and biheteroaryl, any of which is optionally substituted with one or more R2 groups;
- and
- each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound of structural Formula Id
- or a salt or prodrug thereof, wherein:
- W is N or NH;
- Y is N if W is NH;
- Y is NH if W is N;
- R1 is chosen from hydrogen and C1-C6 alkyl;
- L is O;
- R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
- each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl;
- and
- a pharmaceutically acceptable excipient.
A compound of structural Formula Ie
- or a salt or prodrug thereof, wherein:
- W is N or NH;
- Y is N if W is NH;
- Y is NH if W is N;
- R1 is chosen from hydrogen and C1-C6 alkyl;
- L is chosen from NH, NR4, O, CR4═CR5, OCR4R5, and SCR4R5;
- R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
- each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl;
- m and n are independently 1, 2, or 3.
A compound chosen from Examples I-001-I-311, or a salt or prodrug thereof.
A compound of structural Formula Ia
- or a salt or prodrug thereof, wherein:
- W is N or NH;
- Y is N if W is NH;
- Y is NH if W is N;
- R1 is hydrogen or C1-C6 alkyl;
- L is chosen from NH, NR4, S, O, CR4═CR5, OCR4R5, and SCR4R5;
- R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
- A is chosen from monocyclic or bicyclic aryl, monocyclic or bicyclic heteroaryl, biaryl, and biheteroaryl, any of which is optionally substituted with one or more R2 groups;
- and
- each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl.
Dependencies are inferred from the claim text.